{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:45:40Z","timestamp":1767181540248,"version":"build-2238731810"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166627","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T14:21:15Z","timestamp":1480515675000},"page":"e0166627","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy\u2014Results of a Case Control Study"],"prefix":"10.1371","volume":"11","author":[{"given":"Archana","family":"Hinduja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaustubh","family":"Limaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Ravilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Appalnaidu","family":"Sasapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Torbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"R Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/bmj.3.5720.438","article-title":"Thromboembolic complications in myelomatosis","volume":"3","author":"D Catovsky","year":"1970","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"M Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1001\/jama.296.21.2558-c","article-title":"Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer","volume":"296","author":"CL Bennett","year":"2006","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"M Zangari","year":"2001","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"SV Rajkumar","year":"2006","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"EJ Libourel","year":"2010","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"SY Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"B Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy","volume":"116","author":"F van Rhee","year":"2010","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance","volume":"115","author":"B Nair","year":"2010","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"B Barlogie","year":"2014","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/STROKEAHA.108.192218","article-title":"Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists","volume":"40","author":"JD Easton","year":"2009","journal-title":"Stroke"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"HP Adams Jr.","year":"1993","journal-title":"Stroke"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"D Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0404.2006.00709.x","article-title":"Stroke risk factor, pattern and outcome in patients with cancer","volume":"114","author":"YY Zhang","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-009-9818-3","article-title":"Stroke in cancer patients: a risk factor analysis","volume":"94","author":"O Stefan","year":"2009","journal-title":"J Neurooncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1161\/STROKEAHA.112.658625","article-title":"Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology","volume":"43","author":"CJ Schwarzbach","year":"2012","journal-title":"Stroke"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2008.150318","article-title":"Ischaemic stroke subtypes and associated risk factors: a French population based study","volume":"79","author":"Y Bejot","year":"2008","journal-title":"J Neurol Neurosurg Psychiatr.y"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/jnnp.2010.222919","article-title":"Incidence of aetiological subtypes of stroke in a multi-ethnic population based study: the South London Stroke Register","volume":"82","author":"C Hajat","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"BB Navi","year":"2014","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/STROKEAHA.115.008694","article-title":"Cancer in young adults with ischemic stroke","volume":"46","author":"K Aarnio","year":"2015","journal-title":"Stroke"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/01.WNL.0000129912.56486.2B","article-title":"Stroke in patients with cancer: incidence and etiology","volume":"62","author":"DM Cestari","year":"2004","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/CIRCOUTCOMES.109.921858","article-title":"Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke","volume":"3","author":"GC Fonarow","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/STROKEAHA.109.554998","article-title":"Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry","volume":"40","author":"J Putaala","year":"2009","journal-title":"Stroke"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.109.934786","article-title":"Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design","volume":"123","author":"KS Hong","year":"2011","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e88283","DOI":"10.1371\/journal.pone.0088283","article-title":"Stroke patients with a past history of cancer are at increased risk of recurrent stroke and cardiovascular mortality","volume":"9","author":"KK Lau","year":"2014","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"RA Kyle","year":"2003","journal-title":"Mayo Clinic"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients. The Nordic Myeloma Study Group","volume":"53","author":"LM Knudsen","year":"1994","journal-title":"Eur J Haematol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3109\/07853890.2011.582136","article-title":"Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population","volume":"44","author":"MJ Holzmann","year":"2012","journal-title":"Ann Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/STROKEAHA.107.493494","article-title":"Kidney function is related to cerebral small vessel disease","volume":"39","author":"MA Ikram","year":"2008","journal-title":"Stroke"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1161\/STROKEAHA.113.002463","article-title":"Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation","volume":"44","author":"B Ovbiagele","year":"2013","journal-title":"Stroke"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.12.005","article-title":"Chronic kidney disease in patients with ischemic stroke","volume":"21","author":"Y Tsukamoto","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.06.005","article-title":"Acute kidney injury is associated with increased hospital mortality after stroke","volume":"23","author":"M Khatri","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1212\/WNL.0b013e318259e110","article-title":"Proteinuria and clinical outcomes after ischemic stroke","volume":"78","author":"Y Kumai","year":"2012","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1474-4422(14)70026-2","article-title":"Stroke and cerebrovascular diseases in patients with chronic kidney disease","volume":"13","author":"K Toyoda","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/HYPERTENSIONAHA.110.167189","article-title":"Sympathetic activation in chronic kidney disease: out of the shadow","volume":"57","author":"MP Schlaich","year":"2011","journal-title":"Hypertension"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"RT Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/CIRCULATIONAHA.112.104828","article-title":"Klotho. a master regulator of cardiovascular disease?","volume":"125","author":"SM Moe","year":"2012","journal-title":"Circulation"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.HYP.0000168052.00426.65","article-title":"Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy","volume":"46","author":"MF O'Rourke","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1681\/ASN.V133806","article-title":"Role of the microvascular endothelium in progressive renal disease","volume":"13","author":"DH Kang","year":"2002","journal-title":"J Am So of Nephrol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"306189","DOI":"10.4061\/2011\/306189","article-title":"Clinical Interaction between Brain and Kidney in Small Vessel Disease","volume":"2011","author":"M Mogi","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/leu.2015.15","article-title":"Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma","volume":"29","author":"R Khan","year":"2015","journal-title":"Leukemia"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e89386","DOI":"10.1371\/journal.pone.0089386","article-title":"Increased risk of stroke after septicaemia: a population-based longitudinal study in Taiwan","volume":"9","author":"JT Lee","year":"2014","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"D Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref46","first-page":"3377","article-title":"Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma","volume":"8","author":"K Neben","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"SV Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"SV Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"M Zangari","year":"2002","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"JA Zonder","year":"2006","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"SY Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12885-016-2645-y","article-title":"Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen","volume":"16","author":"SH Jung","year":"2016","journal-title":"BMC Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.rce.2013.02.014","article-title":"The impact of the type of hospital on survival of multiple myeloma patients: the MICORE study","volume":"213","author":"R Rios","year":"2013","journal-title":"Rev Clin Esp (Barc)"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1445-5994.2012.02819.x","article-title":"Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre","volume":"43","author":"LJ Fernyhough","year":"2013","journal-title":"Intern Med J"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0175218","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T14:43:42Z","timestamp":1657896222000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166627"}},"subtitle":[],"editor":[{"given":"Jeroen","family":"Hendrikse","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166627","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}